Hello,
Actually we kind have of the same problem. This is mainly due to the sequencing kits sizes from Illumina. They are provided either as 50 cycles or 200 cycles kits.  Sequencing at 75 bp means breaking up the kit in an inconvenient way. I would therefore also favor to sequence either 2x50 bp or 2x100, whereby 2x50 bp has been proven to be sufficient for most of the RNA anaylsis. What's your opinion on this?
Bests,
Marc
On 08.11.2011, at 08:06, Manolis Dermitzakis wrote:

That's odd!
In my view there is no problem and I don't see a difference

Cheers,
Manolis

------------------------------------------
Emmanouil (Manolis) Dermitzakis, PhD
Louis-Jeantet Professor
Department of Genetic Medicine and Development
University of Geneva Medical School
1 Rue Michel-Servet (CMU office 9088)
Geneva 1211
Switzerland

Email: emmanouil.dermitzakis@unige.ch
Tel: +41 (0) 22 379 5483
Fax: +41 (0) 22 379 5706
website: http://funpopgen.unige.ch/

Admin assistant: Ancilla Stefani,
Tel: +41 22 379 5551
e-mail: Ancilla.Stefani@unige.ch
------------------------------------------




P.A.C._t_Hoen@lumc.nl wrote:

Dear Tuuli

Our sequence facility only sequences 2x100 and not 2x75. Is it allowed
to sequence 100bp and throw away the last 25 nucleotides?
Best

Peter





------------------------------------------------------------------------

*From:* geuvadis_rnaseq-bounces@lists.crg.es
[mailto:geuvadis_rnaseq-bounces@lists.crg.es] *On Behalf Of *Tuuli
Lappalainen
*Sent:* Thursday, November 03, 2011 7:26 PM
*To:* geuvadis_rnaseq@lists.crg.es
*Subject:* [Geuvadis_rnaseq] Geuvadis RNAseq Minutes



Dear all,

Enclosed are the Minutes of this afternoon's TC. Action items
copypasted below.

best regards,
Tuuli




*Action items*

-    *Tuuli* will take care of the RNA sample shipments (7/14
November) and inform the contact persons from each lab when the
samples are shipped

-    *Esther* from Barcelona will email Tuuli further specifications
of the miRNAseq protocol, including the minimum coverage per sample
and how exactly that is defined

-    *Tuuli* will send the final version of the sequencing guidelines
to all the labs by November 10

-    *Gabrielle* will set up a mailing list for the analysis group

-    After the labs have received the samples, there is one major
action item for *all partners*: sequencing!



--
Tuuli Lappalainen, PhD
Department of Genetic Medicine and Development
University of Geneva Medical School
CMU / Rue Michel-Servet 1
1211 Geneva 4
Switzerland
Tel. +41-(0)22-3795550
tuuli.lappalainen@unige.ch <mailto:tuuli.lappalainen@unige.ch>
------------------------------------------------------------------------

_______________________________________________
Geuvadis_rnaseq mailing list
Geuvadis_rnaseq@lists.crg.es
http://davinci.crg.es/mailman/listinfo/geuvadis_rnaseq

_______________________________________________
Geuvadis_rnaseq mailing list
Geuvadis_rnaseq@lists.crg.es
http://davinci.crg.es/mailman/listinfo/geuvadis_rnaseq

-------------------------------------------------------------------
Dr. Marc Sultan
Dept. Vertebrate Genomics
Max Planck Institute for Molecular Genetics
Ihnestr. 63-73 
14195 Berlin
Germany
Tel.+49308413-1349
Mob. +49 175 585 3465
Fax +49308413-1128
sultan@molgen.mpg.de